v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses        
Research and development $ 28,642,065 $ 14,298,925 $ 71,991,658 $ 33,830,890
Selling, general and administrative 5,034,782 6,845,045 17,822,207 23,892,011
New Warrants expenses 0 17,424,230 0 104,776,230
Loss from operations (33,676,847) (38,568,200) (89,813,865) (162,499,131)
(Loss)/gain from change in fair value of derivative liabilities (853,575) 285,000 (9,832,500) 6,127,500
Financial investment income 2,802,189 1,492,292 9,039,037 2,380,240
Other financial gain, net 1,616,035 536,562 3,789,856 635,180
Loss before income taxes (30,112,198) (36,254,346) (86,817,472) (153,356,211)
Income tax expense (1,097,647) (490,376) (1,574,382) (620,084)
Net loss $ (31,209,845) $ (36,744,722) $ (88,391,854) $ (153,976,295)
Weighted-average number of shares outstanding – basic (in shares) 275,887,223 272,040,343 275,671,199 247,010,044
Weighted-average number of shares outstanding – diluted (in shares) 275,887,223 272,040,343 275,671,199 247,010,044
Net loss per share basic (in dollars per share) $ (0.11) $ (0.14) $ (0.32) $ (0.62)
Net loss per share diluted (in dollars per share) $ (0.11) $ (0.14) $ (0.32) $ (0.62)

Source